Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

This report analyzes the Israeli pharmaceutical market, focusing on patent protections, generic drug penetration, and the regulatory environment. It identifies key opportunities and challenges for both originator and generic drug manufacturers, and for investors evaluating R&D and market entry strategies. Israel's pharmaceutical sector is characterized by a robust innovation ecosystem, significant R&D investment, and a regulatory framework that balances intellectual property rights with public health access.

What is the Current State of the Israeli Pharmaceutical Market?

The Israeli pharmaceutical market is a significant player in the global healthcare landscape. It demonstrates strong growth driven by a high prevalence of chronic diseases, an aging population, and substantial government investment in healthcare infrastructure and research. The market is diverse, encompassing both innovative branded pharmaceuticals and a substantial generic drug segment.

Market Size and Growth

The Israeli pharmaceutical market was valued at approximately $5.2 billion in 2023 and is projected to reach $7.3 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 7.2% for the forecast period (2023-2028) [1]. This growth is underpinned by an increasing demand for advanced medical treatments and a consistent rise in healthcare expenditure. The country’s advanced healthcare system, characterized by universal coverage provided by four competing health maintenance organizations (HMOs), facilitates widespread adoption of new therapies.

Key Therapeutic Areas

Major therapeutic areas driving market demand include oncology, cardiovascular diseases, central nervous system (CNS) disorders, immunology, and diabetes [2]. These segments benefit from significant R&D activities within Israel's vibrant life sciences sector, attracting both local and international investment.

Generic Drug Penetration

Israel has a well-established generic drug market, with generics accounting for a substantial portion of prescription drug sales by volume. The market penetration of generics is driven by cost-containment policies and the availability of a robust local generic manufacturing and distribution network. As of 2022, generics represent over 70% of the pharmaceutical market by volume [3]. This high penetration rate intensifies competition and necessitates strategic patent management for originator companies.

What are the Dominant Patent Protection Strategies in Israel?

Patent protection in Israel follows international standards, primarily governed by the Patents Law, 1967, and its subsequent amendments. The Israel Patent Office (ILPO) is responsible for examining and granting patents.

Patent Types and Enforcement

Pharmaceutical patents in Israel typically cover novel chemical entities, formulations, methods of treatment, and manufacturing processes. Patent term extension (PTE) mechanisms are available to compensate for patent term lost during the regulatory approval process, a critical consideration for originator drug companies seeking to maximize their market exclusivity.

• Data Exclusivity: Israel provides a period of data exclusivity that runs concurrently with patent protection. For new chemical entities approved after January 1, 2000, a six-year data exclusivity period is granted. If the drug is also patented, the exclusivity period is extended to the longer of either the remaining patent term or 10 years from the date of first marketing authorization [4]. This dual protection is crucial for recouping R&D investments.
• Patent Linkage: While Israel does not have a formal patent linkage system similar to the U.S. Hatch-Waxman Act, the ILPO's examination process and the subsequent regulatory approval by the Ministry of Health (MoH) indirectly influence generic market entry. Generic applicants must demonstrate that their product does not infringe existing valid patents.

Key Patent Litigation Trends

Patent litigation in Israel, particularly concerning pharmaceuticals, often revolves around infringement challenges and patent validity disputes. The courts are increasingly experienced in handling complex intellectual property cases, making robust patent prosecution and defense strategies essential. Settlement agreements between originators and generic manufacturers, similar to those seen in other developed markets, are also observed.

What are the Regulatory Opportunities and Challenges for Drug Manufacturers?

Navigating Israel's regulatory landscape presents both opportunities and challenges for pharmaceutical companies. The Ministry of Health (MoH) is the primary regulatory authority.

Regulatory Pathways for New Drugs

• Marketing Authorization: Obtaining marketing authorization (MA) for new drugs involves submitting a comprehensive dossier to the MoH, including preclinical and clinical data, manufacturing information, and quality control data. The review process generally takes 12-18 months, depending on the complexity of the product and the completeness of the submission [5].
• Fast-Track Review: Israel has implemented mechanisms to expedite the review of innovative medicines, particularly those addressing unmet medical needs or representing significant therapeutic advancements. This can shorten the time to market for novel drugs.

Generic Drug Approval Process

• Abbreviated New Drug Application (ANDA) Equivalent: Generic drug approval requires demonstrating bioequivalence to the reference listed drug (RLD) and providing data on pharmaceutical quality. The MoH reviews these applications to ensure safety, efficacy, and quality. The process is generally efficient, contributing to the high generic penetration.
• "Me-Too" Drugs: Israel also permits the registration of "me-too" drugs, which are similar to existing approved drugs. These require full dossiers but can be approved if they offer a therapeutic advantage or improved safety profile.

Pricing and Reimbursement

• Price Control: The Israeli government employs a price control mechanism for pharmaceuticals, primarily through the Basket Committee, which determines the drugs included in the national health insurance basket. Drug prices are calculated based on a formula that considers prices in other developed countries, with a cap based on the average price in seven major OECD countries (U.S., UK, Germany, France, Italy, Spain, and Canada) [6]. This policy creates a challenging pricing environment for both originators and generics.
• Reimbursement Negotiations: Companies must negotiate with the MoH and HMOs for inclusion in the national health insurance basket and for reimbursement rates. Successful negotiation is critical for market access and commercial success.

Opportunities

• Innovation Hub: Israel's strong life sciences ecosystem, with numerous research institutions and a thriving biotech startup scene, presents opportunities for licensing, co-development, and acquisition of novel drug candidates.
• Early Market Access: The MoH's willingness to consider innovative therapies and the existence of fast-track review pathways can provide early market access for breakthrough drugs.
• Established Infrastructure: The well-developed healthcare and distribution infrastructure facilitates efficient market entry and patient access once regulatory approvals are secured.

Challenges

• Price Controls: Strict price controls limit pricing flexibility and can impact profitability, particularly for high-cost innovative therapies.
• Patent Litigation Complexity: Navigating patent disputes requires substantial legal resources and strategic planning.
• Generic Competition: High generic penetration necessitates aggressive lifecycle management strategies for originator products and efficient market entry strategies for generics.
• Regulatory Hurdles: While generally efficient, the regulatory review process can still be lengthy, and meeting the stringent data requirements for approval demands significant investment.
• Global Harmonization: While Israel aligns with international standards, companies must adapt to specific local regulatory requirements and evolving policies.

What are the Intellectual Property Considerations for Market Entry and Exclusivity?

Understanding the intellectual property (IP) landscape is paramount for any company seeking to enter or compete in the Israeli pharmaceutical market. This includes both obtaining protection for new innovations and navigating existing IP rights.

Patent Filing and Strategy

• National Phase Entry: Companies seeking patent protection in Israel for inventions originating from international patent applications (PCT) must enter the national phase within 30 months of the earliest priority date [7].
• Provisional Patent Applications: While not explicitly defined as "provisional" in the same way as in the U.S., the Israeli patent system allows for the filing of patent applications that establish a priority date.
• Utility Models: Israel does not have a separate system for utility models, similar to some other jurisdictions. Patent protection is the primary mechanism.
• Freedom to Operate (FTO) Analysis: Before launching a new product or initiating R&D, a thorough FTO analysis is crucial to identify any potential infringement of existing Israeli patents. This analysis should encompass active pharmaceutical ingredients (APIs), formulations, manufacturing processes, and methods of use.

Patent Term and Extensions

• Standard Patent Term: Patents in Israel are granted for a term of 20 years from the filing date of the application [8].
• Patent Term Extension (PTE): As previously mentioned, Israel offers PTE to compensate for patent term lost due to the time required for obtaining marketing authorization from the MoH. The extension is calculated based on the period between the patent filing date and the first marketing authorization date, minus a deduction for administrative delays. The maximum extension is five years [4]. This provision is vital for ensuring a reasonable period of market exclusivity for innovative drugs.

Generic Patent Strategies

• "Paragraph IV" Challenges (Analogous): While not formally termed "Paragraph IV," generic companies in Israel must consider how to challenge existing patents or design around them. This often involves detailed analysis of patent claims, prior art searches, and potential invalidity arguments.
• Bioequivalence Studies: The core of a generic drug application is demonstrating bioequivalence to the RLD. This requires robust clinical studies that satisfy the MoH's requirements.
• Process Patents: Generic manufacturers may seek to develop alternative manufacturing processes that do not infringe upon existing process patents held by originators.

Licensing and Collaboration

• In-Licensing: Companies may license patented technologies or drug candidates from Israeli research institutions or biopharmaceutical companies to develop and commercialize them in Israel and globally.
• Out-Licensing: Israeli companies with innovative IP may license their technologies to larger pharmaceutical firms for further development, clinical trials, and commercialization.
• Joint Ventures: Collaborations and joint ventures are common, leveraging the strengths of different entities – for example, combining Israeli R&D expertise with the global commercialization capabilities of multinational corporations.

What are the Key Takeaways for R&D and Investment Decisions?

The Israeli pharmaceutical market offers a dynamic environment characterized by innovation, robust IP protection, and a structured regulatory framework, alongside significant pricing pressures and competitive generic forces.

• Innovation Ecosystem: Israel's strong life sciences sector provides a rich source of novel drug candidates and collaborative opportunities for R&D investment and business development.
• Patent Strength and Strategy: Originator companies must implement comprehensive patent filing and enforcement strategies, including leveraging PTE, to protect their market exclusivity. Generics must conduct thorough FTO analyses and develop effective patent circumvention or challenge strategies.
• Regulatory Navigation: A deep understanding of the MoH's approval processes, data exclusivity provisions, and pricing/reimbursement mechanisms is critical for both originator and generic drug success.
• Pricing Environment: The government's price control policies create a challenging commercial landscape, necessitating careful market forecasting and cost management.
• Generic Market Dominance: The high volume of generic drug sales underscores the need for originators to maximize their exclusivity periods and for generics to focus on efficient R&D, manufacturing, and market entry.

Frequently Asked Questions

1. How does Israel's data exclusivity period compare to that of other major markets like the United States and the European Union?

Israel's six-year data exclusivity period for new chemical entities is shorter than the U.S. (five years for new chemical entities, with potential extensions) and the EU (eight years of data exclusivity plus two years of market exclusivity, extendable to 11 years). However, Israel's provision for extending exclusivity to 10 years from the date of first marketing authorization if the patent term has not expired offers a degree of market protection comparable in practice for some products [4, 9, 10].

2. What is the typical timeline for obtaining marketing authorization for a new drug in Israel?

The typical timeline for obtaining marketing authorization for a new drug in Israel ranges from 12 to 18 months. However, the Ministry of Health offers expedited review pathways for innovative medicines, which can significantly shorten this period for drugs addressing unmet medical needs or representing major therapeutic advancements [5].

3. Are there specific incentives for R&D investment in the Israeli pharmaceutical sector?

Yes, Israel offers various incentives for R&D, including tax benefits, grants from the Israel Innovation Authority (formerly the Office of the Chief Scientist), and support for establishing R&D centers. These incentives aim to foster innovation and attract both domestic and foreign investment in the life sciences [11].

4. How does the price control mechanism in Israel impact the pricing of patented versus generic drugs?

The price control mechanism in Israel applies to both patented and generic drugs, setting reference prices based on international benchmarks and domestic cost considerations. While originators face stringent price ceilings, generics also operate within a framework that emphasizes affordability, contributing to intense price competition once exclusivity periods expire [6].

5. What are the implications of the ongoing global efforts towards pharmaceutical price transparency on the Israeli market?

Global trends towards greater price transparency can influence the Israeli pricing framework. The country’s price referencing system, which relies on prices in other developed nations, means that increased transparency and potential price reductions in those markets could exert downward pressure on prices in Israel. Companies must monitor international pricing dynamics closely [6].

Citations

[1] Mordor Intelligence. (2023). Israel Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). [2] GlobalData. (2023). Pharmaceutical Market Outlook: Israel. [3] Eretz. (2022, October 12). The pharmaceutical market in Israel. Eretz. [4] Israel Patent Office. (n.d.). Patent Term Extension. Retrieved from the Israel Patent Office website. [5] Ministry of Health, Israel. (n.d.). Pharmaceutical Registration. Retrieved from the Ministry of Health website. [6] Ministry of Health, Israel. (2019). The Health Basket for 2020. [7] World Intellectual Property Organization. (n.d.). Israel. In PCT National Entry Information. [8] Israel Patent Office. (n.d.). Patents Law, 1967. [9] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [10] European Medicines Agency. (n.d.). European drug regulatory system. [11] Israel Innovation Authority. (n.d.). R&D Programs. Retrieved from the Israel Innovation Authority website.